Drug Profile
Research programme: antibody therapeutics - GlaxoSmithKline/The Oklahoma Medical Research Foundation
Latest Information Update: 28 Aug 2021
Price :
$50
*
At a glance
- Originator GlaxoSmithKline; Oklahoma Medical Research Foundation
- Developer GSK; Oklahoma Medical Research Foundation
- Class Anti-inflammatories; Antibodies
- Mechanism of Action Cell death inhibitors; Histone modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 28 Aug 2021 No recent reports of development identified for research development in Inflammation in USA
- 24 Jul 2017 Early research in Inflammation in USA (unspecified route)
- 24 Jul 2017 The Oklahoma Medical Research Foundation and GlaxoSmithKline enter into a collaboration agreement to develop antibody therapeutics for tretament of inflammatory disorders